Understanding Immunogenicity in AAV Gene Therapy

A Technical Guide to Assay Design, Validation, and Regulatory Strategy

As AAV-based gene therapies advance into clinical development, managing immunogenicity risk has become essential to ensuring patient eligibility, therapeutic durability, and regulatory approval. This expert-authored white paper delivers a practical, science-backed framework for building immunogenicity assays that are analytically rigorous, clinically relevant, and globally aligned.

Whether you’re designing early-phase protocols or preparing for global filings, this guide provides actionable insights to strengthen your assay strategy and advance your gene therapy program with confidence.

Topics covered:

TAb vs. NAb Assays: In-depth comparison of formats, throughput, sensitivity, and translational relevance
Assay Strategy Across Phases: Guidance on assay selection and validation from preclinical studies to CTA and companion diagnostic development
Navigating Global Regulations: Insights into evolving regulatory expectations in the US (IDE, SRD, Q-submissions) and EU (IVDR)
Validation Best Practices: Technical considerations for cutoff determination, reagent qualification, and global deployment
Linking Immunogenicity & Efficacy: Approaches for integrating immune response data with therapeutic endpoints to refine patient stratification and study design

Download now.

FILL THE FORM BELOW

First Name *

Last Name *

Company Street Address *

Company Suite/Office *

Company Postal/Zip Code *

Company City *

Company State *

Company Country *

By submitting this content request, I have legitimate interest in the content and agree that Precision for Medicine, their partners, and the creators of any other content I have selected may contact me regarding news, products, and services that may be of interest to me.

YesNo